Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is working on targeted protein degradation technology.
Amphista Therapeutics, a UK-based oncology therapy developer spun out of University of Dundee, closed a $53m series B round yesterday co-led by Forbion and Gilde Healthcare.
Pharmaceutical firms Eli Lilly and Novartis also took part in the round, the latter investing through its Novartis Venture Fund. They were joined by BioMotiv and Advent Life Sciences.
Founded in 2017, Amphista Therapeutics is working on treatments that tap into the body’s natural processes to degrade and remove proteins that cause diseases such as cancer and central nervous system disorders.
The financing will allow Amphista to accelerate its pipeline towards the clinic and to expand its platform.
Stefan Luzi, partner at Gilde Healthcare, Rogier Rooswinkel, partner at Forbion, and Florian Müllershausen, managing director at Novartis Venture Fund, have been appointed to Amphista’s board of directors.
Nicola Thompson, chief executive of Amphista, said: “This financing round, led by an outstanding…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
